Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
www.DrugChatter.com/monitoring/
Is it common for doctors to give lipitor savings cards?How does vascepa's potency measure up to epa in chia seeds?How does lipitor's cholesterol lowering effect improve joint flexibility?How does extended tigecycline use impact liver enzyme levels?Is protein intake limited with lipitor?
See the DrugPatentWatch profile for artesunate
When can artesunate be re-administered after an allergic reaction? Current prescribing information for artesunate does not provide a specific waiting period or re-challenge protocol after an allergic reaction. Most product labels advise that the drug should not be re-administered to patients who have experienced a prior serious hypersensitivity reaction. What reactions are considered allergic? Allergic responses to artesunate typically include rash, urticaria, angioedema, bronchospasm, or anaphylaxis. Mild skin reactions are sometimes distinguished from severe systemic reactions, but guidelines still recommend avoiding re-exposure in either case unless a clear alternative is unavailable. How do clinicians decide on re-exposure? In life-threatening malaria where no other agent is suitable, some centers perform a graded challenge under intensive-care monitoring after premedication with antihistamines and corticosteroids. This approach is individualized and not endorsed by the manufacturer or major regulatory bodies. Are there published case reports or protocols? Published literature contains only isolated case reports of successful re-challenge after non-severe reactions; no standardized waiting interval or desensitization schedule exists. Most reports describe re-administration within days to weeks when malaria severity justified the risk. What alternatives exist if re-administration is avoided? Alternative parenteral agents such as intravenous quinine or quinidine remain options in regions where they are available. Oral artemisinin-based combination therapies can be substituted once the patient can tolerate oral intake and parasitemia is controlled. Does artesunate have patent or exclusivity protections that affect availability? Artesunate is off-patent in most markets, and multiple generic manufacturers supply intravenous formulations. No active drug-patent litigation or new exclusivity periods are listed on DrugPatentWatch.com for the intravenous product at this time. Sources [1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208630s000lbl.pdf [2] https://www.drugpatentwatch.com
Other Questions About Artesunate :